These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31965718)

  • 1. The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript.
    Brunac AC; Laprie A; Castex MP; Laurent C; Le Loarer F; Karanian M; Le Guellec S; Guillemot D; Pierron G; Gomez-Brouchet A
    Pediatr Blood Cancer; 2020 May; 67(5):e28185. PubMed ID: 31965718
    [No Abstract]   [Full Text] [Related]  

  • 2. Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases.
    Xu B; Suurmeijer AJH; Agaram NP; Zhang L; Antonescu CR
    Histopathology; 2021 Sep; 79(3):347-357. PubMed ID: 33382123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spindle cell rhabdomyosarcoma in a lumbar vertebra with FUS-TFCP2 fusion.
    Tagami Y; Sugita S; Kubo T; Iesato N; Emori M; Takada K; Tsujiwaki M; Segawa K; Sugawara T; Kikuchi T; Hasegawa T
    Pathol Res Pract; 2019 Aug; 215(8):152399. PubMed ID: 30948206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression.
    Lewin J; Desai J; Smith K; Luen S; Wong D
    Pathology; 2019 Oct; 51(6):655-657. PubMed ID: 31470995
    [No Abstract]   [Full Text] [Related]  

  • 5. Rhabdomyosarcoma With
    Zhong P; Wei S; Xiao H; Zeng Y
    Int J Surg Pathol; 2024 Jun; 32(4):758-766. PubMed ID: 37545350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases.
    Chrisinger JSA; Wehrli B; Dickson BC; Fasih S; Hirbe AC; Shultz DB; Zadeh G; Gupta AA; Demicco EG
    Virchows Arch; 2020 Nov; 477(5):725-732. PubMed ID: 32556562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype.
    Dashti NK; Wehrs RN; Thomas BC; Nair A; Davila J; Buckner JC; Martinez AP; Sukov WR; Halling KC; Howe BM; Folpe AL
    Histopathology; 2018 Sep; 73(3):514-520. PubMed ID: 29758589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype.
    Agaram NP; Zhang L; Sung YS; Cavalcanti MS; Torrence D; Wexler L; Francis G; Sommerville S; Swanson D; Dickson BC; Suurmeijer AJH; Williamson R; Antonescu CR
    Am J Surg Pathol; 2019 May; 43(5):695-702. PubMed ID: 30720533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous rhabdomyosarcoma with FUS::TFCP2 fusion: A case report emphasizing early detection.
    Demirkesen C; Danyeli AE; Yıldız P; Ertekin SS; Yılmaz B; Karahan Sİ; Bahrami A
    J Cutan Pathol; 2023 Dec; 50(12):1059-1064. PubMed ID: 37669767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
    Kim D; Koh Y; Yoon SS
    Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete mimicry: Rhabdomyosarcoma with FUS::TFCP2 fusion masquerading as carcinoma-diagnostic challenge and report of two cases.
    Carrillo-Ng H; Liang Y; Chang S; Afkhami M; Gernon T; Bell D; Arias-Stella JA
    Genes Chromosomes Cancer; 2023 Jul; 62(7):430-436. PubMed ID: 37057803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib shows CNS efficacy in ALK-positive NSCLC.
    Gourd E
    Lancet Oncol; 2018 Oct; 19(10):e520. PubMed ID: 30245054
    [No Abstract]   [Full Text] [Related]  

  • 13. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor.
    Yuan Y; Mapp S; Xu W
    Br J Haematol; 2020 Sep; 190(5):642. PubMed ID: 32537738
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinicopathological features of rhabdomyosarcoma with novel FET::TFCP2 and TIMP3::ALK fusion: report of two cases and literature review.
    Duan FL; Yang H; Gong X; Zuo Z; Qin S; Ji J; Zhou C; Dai J; Guo P; Liu Y
    Histopathology; 2023 Feb; 82(3):478-484. PubMed ID: 36350070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.
    Tomlinson SB; Sandwell S; Chuang ST; Johnson MD; Vates GE; Reagan PM
    Leuk Res; 2019 Aug; 83():106164. PubMed ID: 31226541
    [No Abstract]   [Full Text] [Related]  

  • 18. Rhabdomyosarcoma With
    Ishiyama T; Kato I; Ito J; Matsumura M; Saito K; Kawabata Y; Kato S; Takeyama M; Fujii S
    Int J Surg Pathol; 2023 Aug; 31(5):805-812. PubMed ID: 36437645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
    Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and Molecular Characteristics of Intraosseous Rhabdomyosarcoma Involving Head and Neck Region: A Systematic Review and Meta-Analysis.
    Sivakumar N; Sharma P; Chandra S; Gupta S; Samadi FM; Baghel S
    Pediatr Dev Pathol; 2023; 26(3):299-309. PubMed ID: 37082926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.